Our group has originally developed two broad ligand-directed targeting technology platforms to uncover and exploit functional protein interactions in the context of human disease: combinatorial selection of peptide libraries in patients and hybridoma-free generation of monoclonal antibodies. Essenti

Call for Nominations: Student Awards in Oslerian Medicine